Actively Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Led by BeOne Medicines · Updated on 2026-05-08
217
Participants Needed
27
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
CONDITIONS
Official Title
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide signed informed consent before any study procedures
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Phase 1a: Histologically or cytologically confirmed advanced, metastatic, unresectable immune-sensitive solid tumors with prior standard systemic therapy or not suitable for treatment, and no prior HPK1-targeted therapy
- Phase 1b: Histologically confirmed locally advanced unresectable or metastatic tumors without prior systemic treatment, or with prior curative neo-adjuvant or adjuvant therapy if disease-free for at least 6 months
- At least 1 measurable lesion per RECIST v1.1
- Able to provide archived tumor tissue sample
- Adequate organ function
- Females of childbearing potential willing to use highly effective birth control during the study and for at least 90 days after last BGB-26808 dose, 120 days after last tislelizumab dose, or 180 days after last chemotherapy dose
- Nonsterile males willing to use highly effective birth control during the study treatment period and specified durations after last doses
You will not qualify if you...
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-TIGIT, anti-CTLA4, or other drugs targeting T-cell costimulation or checkpoint pathways
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
- Clinically significant gastrointestinal bleeding within 28 days before first study dose
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis
- Active autoimmune diseases or history of autoimmune diseases that may relapse
- Any malignancy within 3 years before first study dose except the cancer under study or certain locally recurring cancers treated with curative intent
- Systemic corticosteroids (>10 mg prednisone daily or equivalent) or other immunosuppressive medications within 14 days before first study dose
- History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis or acute lung diseases
- Uncontrolled diabetes
- Infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before first study dose
- Other protocol defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 27 locations
1
City of Hope National Medical Center
Duarte, California, United States, 91010-3012
Actively Recruiting
2
University of Southern California Norris Comprehensive
Los Angeles, California, United States, 90033
Actively Recruiting
3
Yale University, Yale Cancer Center
New Haven, Connecticut, United States, 06520-8028
Actively Recruiting
4
Sylvester Cancer Center, University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
5
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601-2191
Actively Recruiting
6
Icahn School of Medicine At Mount Sinai
New York, New York, United States, 10029-6504
Actively Recruiting
7
Providence Portland Medical Center
Portland, Oregon, United States, 97213-2933
Actively Recruiting
8
The University of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Actively Recruiting
9
Southside Cancer Care
Miranda, New South Wales, Australia, NSW 2228
Completed
10
Macquarie University
North Ryde, New South Wales, Australia, NSW 2109
Actively Recruiting
11
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia, SA 5037
Actively Recruiting
12
Linear Clinical Research
Nedlands, Western Australia, Australia, WA 6009
Actively Recruiting
13
The First Affiliated Hospital of Anhui Medical Universitygaoxin Branch
Hefei, Anhui, China, 230022
Actively Recruiting
14
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150000
Actively Recruiting
15
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
16
Tongji Hospital,Tongji Medical College of Hustsino French New City Branch
Wuhan, Hubei, China, 430101
Actively Recruiting
17
The First Hospital of China Medical University Hunnan Branch
Shenyang, Liaoning, China, 110167
Actively Recruiting
18
Jining No1 Peoples Hospital West Branch
Jining, Shandong, China, 272000
Actively Recruiting
19
Yantai Yuhuangding Hospital
Yantai, Shandong, China, 264000
Actively Recruiting
20
Shanghai East Hospital Branch Hospital
Shanghai, Shanghai Municipality, China, 200123
Actively Recruiting
21
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Completed
22
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, Sichuan, China, 610071
Actively Recruiting
23
Hangzhou First Peoples Hospital
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
24
Taizhou Hospital of Zhejiang Province (East)
Taizhou, Zhejiang, China, 317004
Completed
25
Auckland City Hospital
Auckland, New Zealand, 1023
Actively Recruiting
26
Harbour Cancer and Wellness
Auckland, New Zealand, 1023
Actively Recruiting
27
Health New Zealand Te Whatu Ora Lakes Rotorua Hospital
Rotorua, New Zealand, 3010
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here